A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix

Pathology Research and Practice

Volumn 211, Issue 9, 2015, Pages 657-664

  Hara, Kieko ^a   Saito, Tsuyoshi ^a   Hayashi, Takuo ^a   Yimit, Alkam ^a   Takahashi, Michiko ^a   Mitani, Keiko ^a   Takahashi, Makoto ^a   Yao, Takashi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Appendiceal mucinous neoplasm; GNAS; KRAS; Mismatch repair gene; Mutation; TP53

Indexed keywords

B RAF KINASE; BETA CATENIN; K RAS PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; CTNNB1 PROTEIN, HUMAN; GNAS PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TELOMERASE; TERT PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; APPENDICEAL MUCINOUS TUMOR; APPENDIX TUMOR; ARTICLE; BRAF GENE; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CTNNB1 GENE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GNAS GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NONSENSE MUTATION; ONCOGENE K RAS; TERT GENE; TP53 GENE; TUMOR GROWTH; ADENOCARCINOMA, MUCINOUS; AGED; APPENDICEAL NEOPLASMS; CANCER GRADING; CHEMISTRY; COMPARATIVE STUDY; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROMOTER REGION; VERY ELDERLY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; APPENDICEAL NEOPLASMS; BETA CATENIN; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS P21(RAS); TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938751113     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2015.06.004     Document Type: Article

References (36)

1. Misdraji J., Yantiss R.K., Graeme-Cook F.M., Balis U.J., Young R.H. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am. J. Surg. Pathol. 2003, 27:1089-1103.
2. Misdraji J. Appendiceal mucinous neoplasms. Arch. Pathol. Lab. Med. 2010, 134:864-870.
3. Zauber P., Berman E., Marotta S., Sabbath-Solitare M., Bishop T. Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix. Scand. J. Gastroenterol. 2011, 46:869-874.
4. Kabbani W., Houlihan P.S., Luthra R., Hamilton S.R., Rashid A. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod. Pathol. 2002, 15:599-605.
5. Nishikawa G., Sekine S., Ogawa R., Matsubara A., Mori T., Taniguchi H., et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br. J. Cancer 2013, 108:951-958.
6. Carr N.J., Emory T.S., Sobin L.H. Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis, and expression of p53, CD44, bcl-2. Arch. Pathol. Lab. Med. 2002, 126:837-841.
7. Shetty S., Thomas P., Ramanan B., Sharma P., Govindarajan V., Loggie B. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. J. Surg. Res. 2013, 180:97-103.
8. Taggart M.W., Galbincea J., Mansfield P.F., Fournier K.F., Royal R.E., Overman M.J., et al. High-level microsatellite instability in appendiceal carcinomas. Am. J. Surg. Pathol. 2013, 37:1192-1200.
9. Yantiss R.K., Panczykowski A., Misdraji J., Hahn H.P., Odze R.D., Rennert H., et al. A comprehensive study of nondysplastic and dysplastic serrated polyps of the vermiform appendix. Am. J. Surg. Pathol. 2007, 31:1742-1753.
10. Chu P.G., Chung L., Weiss L.M., Lau S.K. Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am. J. Surg. Pathol. 2011, 35:1830-1836.
11. Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
12. Koelsche C., Sahm F., Capper D., Reuss D., Sturm D., Jones D.T., et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013, 126:907-915.
13. Melo M., da Rocha A.G., Vinagre J., Batista R., Peixoto J., Tavares C., et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 2014, 99:E754-E765.
14. Rachakonda P.S., Hosen I., de Verdier P.J., Fallah M., Heidenreich B., Ryk C., et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:17426-17431.
15. Campanella N.C., Celestino R., Pestana A., Scapulatempo-Neto C., de Oliveira A.T., Brito M.J., et al. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Eur. J. Hum. Genet. 2014, [Epub ahead of print, September 24]. 10.1038/ejhg.2014.195.
16. Killela P.J., Reitman Z.J., Jiao Y., Bettegowda C., Agrawal N., Diaz L.A., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:6021-6026.
17. Carr N.J., Sobin L.H. Adenocarcinoma of the appendix. WHO Classification of Tumours of the Digestive System 2010, 122-128. IRAC Press, Lyon. 4th edition.
18. Ronnett B.M., Kurman R.J., Zahn C.M., Shmookler B.M., Jablonski K.A., Kass M.E., Sugarbaker P.H. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum. Pathol. 1995, 26:509-524.
19. Mukherjee A., Parvaiz A., Cecil T.D., Moran B.J. Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence. Eur. J. Gynaecol. Oncol. 2004, 25:411-414.
20. Clememti E., Malgaretti N., Meldolesi J., Taramelli R. A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours. Oncogene 1990, 5:1059-1061.
21. Idowu B.D., Al-Adnani M., O'Donnell P., Yu L., Odell E., Diss T., et al. A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. Histopathology 2007, 50:691-704.
22. Delaney D., Diss T.C., Presneau N., Hing S., Berisha F., Idowu B.D., et al. GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod. Pathol. 2009, 22:718-724.
23. Yamada M., Sekine S., Ogawa R., Taniguchi H., Kushima R., Tsuda H., et al. Frequent activating GNAS mutations in villous adenoma of the colorectum. J. Pathol. 2012, 228:113-118.
24. Furukawa T., Kuboi Y., Tanji E., Yoshida S., Hatori T., Yamamoto M., et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci. Rep. 2011, 1:161.
25. Sasaki M., Matsubara T., Nitta T., Sato Y., Nakanuma Y. GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct. PLoS One 2013, 8:e81706.
26. Alakus H., Babicky M.L., Ghosh P., Yost S., Jepsen K., Dai Y., et al. Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med. 2014, 6:43.
27. Singhi A.D., Davison J.M., Choudry H.A., Pingpank J.F., Ahrendt S.A., Holtzman M.P., et al. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Hum. Pathol. 2014, 45:1737-1743.
28. Liu X., Mody K., de Abreu F.B., Pipas J.M., Peterson J.D., Gallagher T.L., et al. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin. Chem. 2014, 60:1004-1011.
29. Leroy B., Fournier J.L., Ishioka C., Monti P., Inga A., Fronza G., Soussi T. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013, 41:D962-D969.
30. Davison J.M., Choudry H.A., Pingpank J.F., Ahrendt S.A., Holtzman M.P., Zureikat A.H., Zeh H.J., Ramalingam L., Zhu B., Nikiforova M., Bartlett D.L., Pai R.K. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod. Pathol. 2014, 27:1521-1539.
31. Yoon S.O., Kim B.H., Lee H.S., Kang G.H., Kim W.H., Kim Y.A., et al. Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors. Mod. Pathol. 2009, 22:1102-1112.
32. Nomura R., Saito T., Mitomi H., Hidaka Y., Lee S.Y., Watanabe S., et al. GNAS mutation as an alternative mechanism of activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type. Hum. Pathol. 2014, 45:2488-2496.
33. Nenutil R., Smardova J., Pavlova S., Hanzelkova Z., Muller P., Fabian P., et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J. Pathol. 2005, 207:251-259.
34. Yajima N., Wada R., Yamagishi S., Mizukami H., Itabashi C., Yagihashi S. Immunohistochemical expressions of cytokeratins, mucin core proteins, p53, and neuroendocrine cell markers in epithelial neoplasm of appendix. Hum. Pathol. 2005, 36:1217-1225.
35. Bi S., Lanza F., Goldman J.M. The abnormal p53 proteins expressed in CML cell lines are non-functional. Leukemia 1993, 7:1840-1845.
36. Sakai T., Furihata T., Kawamata H., Omotehara F., Shinagawa Y., Imura J., et al. Molecular and genetic characterization of a non-metastatic human esophageal cancer cell line, T.Tn expressing non-functional mutated p53. Int. J. Oncol. 2002, 21:547-552.